title: Changes in serum osteocalcin levels in the follow-up of kidney transplantation.
abstract: Serum osteocalcin, total alkaline phosphatase, intact parathyroid hormone (PTH), creatinine, calcium, and phosphate were determined in 23 kidney cadaveric allograft recipients, immediately before and 0.5, 1, 3 and 6 months after surgery. Immunosuppressive treatment was based on low doses of corticosteroids and cyclosporin combined with antilymphoblast globulin. The decrease in serum creatinine was accompanied by falling PTH concentrations. Serum osteocalcin levels were higher than normal before kidney transplantation and diminished at 0.5 and 1 month after surgery. Significant increases in serum osteocalcin concentrations were observed 3 and 6 months after kidney transplantation with a significant correlation with alkaline phosphatase levels. The increase in serum osteocalcin levels observed in our transplanted patients is not related with a parallel increase in serum creatinine levels nor with an increment in PTH levels; it seems to reflect an increase in the osteoblastic activity, which is not altered by steroid therapy.
authors.affiliation: Hormone Unit (Biochemistry Service), Ciudad Sanitaria y Universitaria de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain.
authors.forename: M R
authors.initials: MR
authors.lastname: Bonnin
authors.forename: M T
authors.initials: MT
authors.lastname: Gonzalez
authors.forename: J M
authors.initials: JM
authors.lastname: Griñó
authors.forename: J M
authors.initials: JM
authors.lastname: Cruzado
authors.forename: J
authors.initials: J
authors.lastname: Bover
authors.forename: J M
authors.initials: JM
authors.lastname: Martinez
authors.forename: M A
authors.initials: MA
authors.lastname: Navarro
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000961:Antilymphocyte Serum / Q000008:administration & dosage / Q000627:therapeutic use; D015415:Biomarkers / Q000097:blood; D001842:Bone and Bones / Q000378:metabolism; D016572:Cyclosporine / Q000008:administration & dosage / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D005938:Glucocorticoids / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D006962:Hyperparathyroidism, Secondary / Q000209:etiology / Q000378:metabolism*; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000627:therapeutic use; D016030:Kidney Transplantation; D008297:Male; D008875:Middle Aged; D015675:Osteocalcin / Q000097:blood*; D011241:Prednisone / Q000008:administration & dosage / Q000627:therapeutic use
chemical_list: D000961:Antilymphocyte Serum; D015415:Biomarkers; D005938:Glucocorticoids; D007166:Immunosuppressive Agents; D015675:Osteocalcin; D016572:Cyclosporine; D011241:Prednisone